RAASi therapy benefit and challenges in cardio-renal patients.

1 May 2017 (12:50 - 13:05)

Organised by:

About the speaker

Professor Lars Lund

Karolinska University Hospital, Stockholm (Sweden)

5 More presentations in this session

Presentation thumbnail

Welcome and introduction.

Presentation thumbnail

Treatment strategies to manage hyperkalemia and control potassium levels.

Professor S. Anker (Berlin, DE)

Presentation thumbnail

Changing the treatment paradigm of hyperkalemia management to enable and optimize RAASi therapy.

Professor J. Butler (Dallas, US)

Presentation thumbnail

Panel discussion.

Professor B. Pitt (Ann Arbor, US)

Presentation thumbnail

Summary and conclusions.

Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Access the full session

Session thumbnail

Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels

The Event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

1 May 2017 12:50 CET

You may be interested in

Congress Session

Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?

19 May 2025

Congress Presentation

Use of renin-angiotensin-aldosteron inhibitors in older adults: do we really need target doses?

29 June 2021

Congress Presentation

Experience of using sacubitril - valsartan in dialysis patients

29 June 2021

Congress Presentation

Continuing foundational therapy in symptomatic heart failure: The key role of RAASi-based therapy

20 May 2023

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources